Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7515.092 | 0.9402 | 0.9000 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7515.092 | 0.9001 | 0.8324 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7515.092 | 0.5620 | 0.2385 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7515.092 | 0.0097 | -0.9578 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7515.092 | 0.0089 | -0.9604 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7516.092 | 0.9121 | 0.8400 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7516.092 | 0.9398 | 0.8906 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7516.092 | 0.9341 | 0.8802 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7516.092 | 0.9944 | 0.9899 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7516.092 | 1.0103 | 1.0187 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7516.092 | 1.0310 | 1.0562 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7516.092 | 0.4690 | 0.0070 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7516.092 | 0.0092 | -0.9715 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7516.092 | 0.0009 | -0.9966 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7517.091 | 0.8910 | 0.8570 | 1.5552 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7517.091 | 0.9093 | 0.8814 | 1.5552 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7517.091 | 0.9094 | 0.8816 | 1.5552 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7517.091 | 0.9208 | 0.8967 | 1.5552 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7517.091 | 1.0058 | 1.0075 | 1.5552 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7517.091 | 0.7217 | 0.6216 | 1.5552 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7517.091 | 0.4007 | 0.1108 | 1.5552 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7517.091 | 0.0103 | -0.8943 | 1.5552 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7517.091 | 0.0203 | -0.8366 | 1.5552 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7518.091 | 0.9750 | 0.9690 | 1.6174 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7518.091 | 0.9587 | 0.9486 | 1.6174 |